EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer

Rosalin Mishra, Mary Kate Kilroy, Wasim Feroz, Hima Patel, Joan T Garrett

Molecular Carcinogenesis · 2024

DOI: 10.1002/mc.23743 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2024. Written by Rosalin Mishra and 4 co-authors. Institution: James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA. Major MEDLINE topics: Receptor, ErbB-3, Mutation, Cell Proliferation, Signal Transduction. Cited 2 times so far (Crossref); 59 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: American Cancer society.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

HER3 is mutated in ~2%–10% of cancers depending on the cancer type. We found the HER3‐V104L mutation to be activating from patient‐derived mutations introduced via lentiviral transduction in HER3KO HER2 + HCC1569 breast cancer cells in which endogenous HER3 was eliminated by CRISPR/Cas9. Cells expressing HER3‐V104L showed higher p‐HER3 and p‐ERK1/2 expression versus cells expressing wild‐type HER3 or HER3‐V104M. Patients whose tumor expressed the HER3 V104L variant had a reduced probability of overall survival compared to patients lacking a HER3 mutation whereas we did not find a statistically significant difference in overall survival of various cancer patients with the HER3 V104M mutation. Our data showed that HER2 inhibitors suppressed cell growth of HCC1569HER3KO cells stably expressing the HER3‐V104L mutation. Cancer cell lines (SNU407, UC15 and DV90) with endogenous HER3‐V104M mutation showed reduced cell proliferation and p‐HER2/p‐ERK1/2 expression with HER2 inhibitor treatment. Knock down of HER3 abrogated cell proliferation in the above cell lines which were overall more sensitive to the ERK inhibitor SCH779284 versus PI3K inhibitors. HER3‐V104L mutation stabilized HER3 protein expression in COS7 and SNUC5 cells. COS7 cells transiently transfected with the HER3‐V104L mutation in the presence of HER binding partners showed higher expression of p‐HER3, p‐ERK1/2 versus HER3‐WT in a NRG‐independent manner without any change in AKT signaling. Overall, this study shows the clinical relevance of the HER3 V104L and the V104M mutations and its response to HER2, PI3K and ERK inhibitors.

Subjects

MeSH terms (MEDLINE)

Receptor, ErbB-3MutationCell ProliferationSignal TransductionErb-b2 Receptor Tyrosine KinasesHumansFemaleCell Line, TumorDrug Resistance, NeoplasmBreast NeoplasmsAnimalsAntineoplastic AgentsNeoplasms

Author keywords

HER3cell growthdrug sensitivitymutationstargeted therapy

Substances

Receptor, ErbB-3Erb-b2 Receptor Tyrosine KinasesAntineoplastic AgentsERBB3 protein, humanERBB2 protein, human

Authors and institutions

  • James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.

Funding

  • American Cancer society

Cite

APA

Mishra, R., Kilroy, M. K., Feroz, W., Patel, H., & Garrett, J. T. (2024). HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23743

Vancouver

Mishra R, Kilroy MK, Feroz W, Patel H, Garrett JT. HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23743

BibTeX
@article{Mishra2024,
  author = {Mishra, Rosalin and Kilroy, Mary Kate and Feroz, Wasim and Patel, Hima and Garrett, Joan T},
  title = {HER3 V104 mutations regulate cell signaling, growth, and drug sensitivity in cancer},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  doi = {10.1002/mc.23743}
}
Start for free →